Improving lung cancer treatment by targeting genetic factors
Targeting Epigenetic Heterogeneity to Improve Lung Cancer Immunotherapy Response
This study is looking at ways to make immunotherapy work better for people with lung cancer, especially those with squamous cell carcinoma, by using a special treatment to change the tumor environment and boost the immune system's ability to fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10818680 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of immunotherapy for lung cancer, particularly in patients with squamous cell carcinoma. The approach involves using an epigenetic inhibitor to modify the tumor environment and improve the immune response against cancer cells. By studying both mouse models and patient-derived organoid cultures, the researchers aim to understand how these treatments can increase the presence of immune-activating cells and reduce immunosuppressive factors. The ultimate goal is to identify the mechanisms that lead to successful or unsuccessful treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with squamous cell lung carcinoma who have not responded well to existing treatments.
Not a fit: Patients with other types of lung cancer or those who have not been diagnosed with squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for lung cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in enhancing immunotherapy responses through similar epigenetic approaches, indicating potential for success in this study.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Brainson, Christine Fillmore — University of Kentucky
- Study coordinator: Brainson, Christine Fillmore
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.